Skip to content

Neuropathic Pain in Psoriatic Arthritis

Evaluation of Neuropathic Pain in Patients With Psoriatic Arthritis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05223049
Enrollment
45
Registered
2022-02-03
Start date
2022-01-22
Completion date
2022-03-15
Last updated
2022-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriatic Arthritis

Keywords

Neuropathic Pain, Psoriatic Arthritis

Brief summary

Pathogenesis of inflammatory diseases is suitable for eliciting neuropathic pain. The aim of this study is to evaluate the frequency of NP among PsA patients and relationship between disease activity, quality of life, functionality, and other numerous factors.

Detailed description

Neuropathic pain (NP) is the pain arising from a primary lesion or a dysfunction of nervous system. NP can affect central or peripheral nervous system and can be caused by numerous factors such as inflammation or neuroplastic changes. Inflammation can sensitize nociceptors in sensory nerves by promoting prostaglandin E2 and I2 secretion thus, cause neuropathic pain. Besides, a mixed pain pattern with neuropathic components is thought to be developed in chronic pain conditions. In this point of view, pathogenesis of inflammatory diseases is suitable for eliciting NP. In arthritic joints, even non-arthritic tissues are affected by the disease and a condition called peripheral sensitization develops. Previous studies about NP and inflammatory diseases link have focused on rheumatoid arthritis and number of studies about NP and psoriatic arthritis (PsA) is limited. In this manner the aim of this study is to evaluate the frequency of NP among PsA patients and relationship between disease activity, quality of life, functionality, and other numerous factors.

Interventions

The painDETECT questionnaire was specifically developed to detect neuropathic pain components in adult patients with low back pain. It is also used in detecting the neuropathic pain in rheumatic diseases. A score between ≤12 represents a nonneuropathic pain, ≥13 and ≤18 represents a possible neuropathic pain, while a score of ≥19 represents a neuropathic pain.

OTHERDouleur Neuropathique 4 questionnaire (DN4)

DN4 is a clinician-administered questionnaire consisting of 10 items. Seven items related to pain quality (i.e. sensory and pain descriptors) are based on an interview with the patient and 3 items based on the clinical examination. A score of ≥4 represents a neuropathic pain.

The 36-Item Short Form Survey (SF-36) is a self-reported measure of health. It comprises 36 questions which cover eight domains of health. 1) Limitations in physical activities because of health problems. 2) Limitations in social activities because of physical or emotional problems 3) Limitations in usual role activities because of physical health problems 4) Bodily pain 5) General mental health (psychological distress and well-being) 6) Limitations in usual role activities because of emotional problems 7) Vitality (energy and fatigue) 8) General health perceptions. Each domain is scored between 0 and 100 and a higher score represents a better outcome.

OTHERSpondyloarthritis Research Consortium of Canada Enthesitis Index (SPARCC)

SPARCC was created as a measure for enthesitis in spondyloarthritis in general. It assesses 16 enthesial sites. Total number of the enthesitis is the total score of the evaluation. Total score is between 0 and 16, and higher scores represent a worse outcome.

Self reported pain scored between 0 (minimum)-10 (maximum). Higher scores represent a worse outcome.

DAPSA includes a 68/66 joint count summed with a patient global, patient pain score, and C- reactive protein level. The DAPSA provides a continuous score of arthritis activity and has validated cut points for remission (\< 4) and low disease activity (\< 14).

Sponsors

Bezmialem Vakif University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* being aged≥18 * being diagnosed PSA according to CASPAR criteria

Exclusion criteria

* additional conditions that could cause neuropathic pain (e.g. radiculopathy, polyneuropathy, depression, fibromyalgia) * history of fracture or surgery * endocrinopathies that could cause neuropathic pain (e.g. DM) * malignancy

Design outcomes

Primary

MeasureTime frameDescription
Frequency neuropathic pain in psoriatic arthritis patients1 dayThe frequency of neuropathic pain in the PSA patients included in the study according to painDETECT and DN4 scores.
Disease activity in Psoriatic arthritis (DAPSA) score in two groups1 dayThe statistical difference between two groups in terms of disease activity
Numeric Rating Scale (rest, movement) in two groups1 dayThe statistical difference between two groups in terms of disease activity
Short form-36 survey in two groups1 dayThe statistical difference between two groups in terms of SF-36 and subdomains
SPARCC enthesitis index in two groups1 dayhe statistical difference between two groups in terms of SPARCC

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026